Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers

Gynecologic Oncology

Volumn 92, Issue 1, 2004, Pages 192-196

  Escobar, Pedro F ^a   Markman, Maurie ^a   Rose, Peter ^b   Zanotti, Kristine ^a   Webster, Kenneth ^a   Belinson, Jerome ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Carboplatin; Irinotecan; Ovarian cancer; Paclitaxel

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DRUG DERIVATIVE; FAMOTIDINE; IRINOTECAN; LOPERAMIDE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; OVARY CANCER; OVARY TUMOR; PERITONEUM CANCER; PERITONEUM TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA; UTERINE TUBE TUMOR;

EID: 0742272530     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.10.003     Document Type: Article

References (19)

1. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y.et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
2. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E.et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer. Three-year results. J. Natl. Cancer Inst. 92:2000;699-708.
3. Covens A., Carey M., Bryson P., Verma S., Fung M.F.K., Johnson M. Systemic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol. Oncol. 85:2002;71-80.
4. Vasey P.A. Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin vs. paclitaxel-carboplatin in epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 21:202a, 2002.e II, III, or IV epithelial ovarian cancer. Gynecol. Oncol. 85:2002;71-80.
5. Rothenberg M.L. CPT-11: an original spectrum of clinical activity. Semin. Oncol. 23(1)(Suppl. 3):1996;21-26.
6. Kunimoto T., Nitta K., Tanaka T., Uehara N., Baba H., Takeuchi M.et al. Antitumor activity of 7-ethyl-10[4-(1-piperidino)]carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res. 47:1987;5944-5947.
7. Look K.Y., Blessing J.A., Levenbach C., Kohler M., Chafe W., Roman L. A phase II trial of CPT-11 in recurrence squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol. Oncol. 70:1998;334-338.
8. Verschragen C.F., Levy T., Kudelka A.P., Llerena E., Ende K., Freedman R.S.et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J. Clin. Oncol. 15:1997;625-631.
9. Bodurka D.C., Levenback C., Wolf J.K., Gano J., Wharton J.T., Kavanagh J.J.et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J. Clin. Oncol. 21:2003;291-297.
10. Fukuda M., Oka M., Soda H., Terashi K., Kawabata S., Nakatomi K.et al. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin. Cancer Res. 5:1999;3963-3969.
11. Socinskin M.A., Sandler A.B., Israel V.K., Gillenwater H.H., Miller L.L., Locker P.K.et al. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma. Cancer. 95:2002;1520-1527.
12. Rustin G.J.S., Nelstrop A.E., Tuxen M.K., Lambert H.E. Defining progression of ovarian carcinoma during follow-up according to CA:125: a North Thames Ovary Group study. Ann. Oncol. 7:1996;361-364.
13. Rustin G.J.S., Marples M., Nelstrop A.E., Mahmoudi M., Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J. Clin. Oncol. 19:2001;4054-4057.
14. Markman M., Hall J., Spitz D., Weiner S., Carson L., VanLe L.et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel refractory ovarian cancer. J. Clin. Oncol. 20:2002;2365-2369.
15. Markman M., Glass T., Smith H.O., Hatch K.D., Weiss G.R., Taylor S.A.et al. Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial. Gynecol. Oncol. 88:2003;282-288.
16. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol. Oncol. 789:2000;369-372.
17. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol. Oncol. 79:2000;116-119.
18. Markman M., Kennedy A., Webster K., Peterson G., Kulp B., Belinson J. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J. Clin. Oncol. 19:2001;1901-1905.
19. Coleman R.L. Emerging role of topotecan in front-line treatment of carcinoma of the ovary. Oncologist. 7(Suppl. 5):2002;46-55.